2X7.F OrthoPediatrics Corp
- Market cap
- EUR 768M
- P/E
- -
- P/B
- 2.56x
- ROE
- -9.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2X7.F undervalued?
Graham numberThe Graham number of OrthoPediatrics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OrthoPediatrics Corp fundamental analysis
No fundamental analysis for OrthoPediatrics Corp yet.
OrthoPediatrics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OrthoPediatrics Corp
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, can…
Full company profileOrthoPediatrics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OrthoPediatrics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 37.3M | 45.6M | 57.6M | 72.6M | 71.1M | 98.0M | 122M | 149M | 205M | 236M | 270M |
| Gross Profit | 26.4M | 34.5M | 42.7M | 54.6M | 55.0M | 73.4M | 90.7M | 111M | 149M | 173M | 200M |
| Operating Income | -6.13M | -6.47M | -9.55M | -9.08M | -20.4M | -17.9M | -21.8M | -25.8M | -29.5M | -29.0M | -21.4M |
| EBITDA | - | -4.04M | -6.88M | -4.48M | -22.2M | -4.46M | 11.8M | -8.38M | -10.4M | -7.88M | 625K |
| Net Income | -6.57M | -8.93M | -12.0M | -13.7M | -32.9M | -16.3M | 1.26M | -21.0M | -37.8M | -39.6M | -31.7M |
| EPS | - | -0.71 | -0.83 | -0.82 | -1.68 | -0.83 | 0.05 | -0.90 | -1.56 | -1.58 | -1.21 |
| Balance Sheet | |||||||||||
| Total Assets | 30.7M | 82.3M | 112M | 195M | 320M | 304M | 428M | 439M | 473M | 509M | 509M |
| Total Liabilities | 24.7M | 34.8M | 30.4M | 52.2M | 85.6M | 78.9M | 49.1M | 61.7M | 119M | 162M | 170M |
| Shareholders' Equity | 5.99M | 47.5M | 81.7M | 142M | 235M | 225M | 379M | 377M | 355M | 347M | 339M |
| Cash & Short-term Investments | 1.61M | 42.6M | 60.7M | 70.8M | 28.8M | 7.64M | 8.99M | 31.1M | 43.8M | 19.6M | 17.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.12M | -7.22M | -15.6M | -17.8M | -18.5M | -13.1M | -21.8M | -27.0M | -27.0M | -4.85M | 2.86M |
| Capital Expenditure | 4.75M | 5.21M | 5.25M | 11.8M | 10.5M | 8.10M | 10.0M | 16.9M | 14.3M | 11.1M | 11.6M |
| Free Cash Flow | - | -13.8M | -21.0M | -29.9M | -29.8M | -29.1M | -31.8M | -43.9M | -41.3M | -16.0M | -8.76M |
| Ratios | |||||||||||
| ROE | -109.6% | -18.8% | -14.7% | -9.6% | -14.0% | -7.2% | 0.3% | -5.6% | -10.7% | -11.4% | -9.3% |
| ROA | -21.4% | -10.9% | -10.7% | -7.1% | -10.3% | -5.3% | 0.3% | -4.8% | -8.0% | -7.8% | -6.2% |
| Net Profit Margin | -17.6% | -19.6% | -20.9% | -18.9% | -46.3% | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% | -11.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OrthoPediatrics Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 5.97M | 0.47 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns OrthoPediatrics Corp
- Insiders 29.69%
- Institutions 68.84%
- Public & others 1.46%
- Shares outstanding 26.1M
- Free float 18.2M
OrthoPediatrics Corp company profile
- Company name
- OrthoPediatrics Corp
- Ticker
- 2X7.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 602
- Fiscal year end
- December
- Address
- 2850 Frontier Drive, Warsaw, IN, United States, 46582
- Phone
- 574 268 6379
- Website
- orthopediatrics.com
About OrthoPediatrics Corp
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
OrthoPediatrics Corp management
9- Mr. Mark C. ThrodahlExecutive Chairman · born 1951
- Mr. David R. BaileyPresident, CEO & Director · born 1979
- Mr. Fred L. HiteCFO, Principal Financial & Accounting Officer, COO and Director · born 1968
- Mr. Daniel J. Gerritzen J.D.Executive VP of Legal, General Counsel & Secretary · born 1970
- Mr. Gregory A. OdlePresident of Scoliosis · born 1970
- Mr. Joseph W. HauserPresident of Trauma, Deformity Correction & OPSB · born 1982
- Mr. Kevin L. Unger CHE, MBA/MSHAPresident of Enabling Technologies · born 1972
- Mr. Mark KarshnerSenior Vice President of International Sales
- Ray GarrisonSenior Vice President of Quality & Regulatory and Clinical